The P-III (DREAMM-7) trial evaluates the safety and efficacy of Blenrep + BorDex vs daratumumab + BorDex as a 2L treatment of patients (n=494) with r/r multiple myeloma. The 1EP of the study includes PFS & 2EPs include OS, DoR & MRD
The results depicted a 59% reduction in risk of disease progression or death with Blenrep + BorDex vs daratumumab + BorDex, PFS of 36.6mos. vs 13.4mos., ORR of 82.7% vs 71.3%, CR of 20.6% vs 12%, PR of 16.9% vs 25.1%, MRD rate of 24.7 vs 9.6 & mDoR of 35.6mos. vs 17.8mos. Additionally, the results are expected to be presented at ASCO 2024
Blenrep is an ADC comprising a humanized B-cell maturation antigen mAb conjugates with the cytotoxic agent auristatin F via a non-cleavable linker
Ref: GSK | Image: GSK
Related News:- GSK Reports the Results for Blenrep (belantamab mafodotin) in P-III Clinical Trial for the Treatment of Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
